Oculis (OCS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Late-stage pipeline advanced: PREDICT-1 completed randomization, while PIONEER-1 continued site activation and enrollment; topline PREDICT-1 results are expected around year-end 2026.
Privosegtor’s Phase 2 biomarker findings and prior functional and structural results support its potential neuroprotective activity in optic neuritis and acute MS relapses.
Financial highlights
Cash, cash equivalents and short-term investments totaled CHF 210.3M ($252.0M) at Sept. 30, 2026, versus CHF 213.0M ($268.7M) at Dec. 31, 2025; runway extends into 2H 2029.
Q3 2026 R&D expense was CHF 15.1M ($18.5M), versus CHF 14.1M ($17.6M) in Q3 2025; G&A was CHF 8.6M ($10.6M), versus CHF 6.4M ($8.0M).
9M 2026 net loss was CHF 57.1M ($71.7M), versus CHF 75.4M ($89.7M) in 9M 2025; lower loss reflected warrant fair-value gains and favorable FX movements.
Outlook and guidance
PREDICT-1 topline results are anticipated around year-end 2026; positive results could support Licaminlimab as a precision medicine for TNFR1-mediated dry eye disease.
FDA IND clearance for Privosegtor trials in acute MS relapses is expected in Q4 2026, following positive FDA feedback on the regulatory pathway.
R&D Day is scheduled for Dec. 8, 2026, with updates planned on Licaminlimab and Privosegtor programs, including optic neuritis, NAION and acute MS relapses.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference